ReviewArchives of toxicology2022
Recommendations on dose level selection for repeat dose toxicity studies.
Review in Archives of toxicology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Progress, critical challenges, and translational prospects of intranasal administration of botanical essential oils for the treatment of depression.Frontiers in pharmacology · 2025Pooled it
- Germ cell risk assessment of combined exposure to monosodium glutamate and bisphenol A in male SD rat: deciphering the molecular mechanisms.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- RefLaTEA: a robust visualization and analysis framework leveraging background data for enhanced insight.MethodsX · 2026Article
- Rabbit Immune Cell Function: In Vitro Assays for Immunological Assessment Studies Using Flow Cytometry.Biotech (Basel (Switzerland)) · 2026Article
- Structural Optimization of Pterostilbene, a Promising Lead Molecule, and Evaluation of Its Derivatives via ADMET Prediction and In Vitro/In Vivo Anti-Cerebral Ischemic Activity.International journal of molecular sciences · 2026Article
- Article
- A Novel Nutritional, Thirst-Free Drink Alleviates Type 2 Diabetes: From Toxicity Studies to Human Clinical Trials.BioMed research international · 2026Article
- Toxicological Evaluation of the Liver and Kidneys of Rats Exposed toJournal of experimental pharmacology · 2026Article
- From Genetic Engineering to Preclinical Safety: A Study on Recombinant Human Interferons.International journal of molecular sciences · 2025Article
- A CpG Epigenetic Switch Reverts PFAS ToxicityAn In Vitro Study.Environment & health (Washington, D.C.) · 2025Article
- Microsampling in toxicology studies - maximising the scientific, business and 3Rs advantages.Toxicology research · 2025Article
- Nutrients and phytochemicals characterisations, acute and sub-acute oral toxicity studies of BobyGuard C, a polyherbal nutraceutical with anti-breast cancer properties.Frontiers in toxicology · 2025Article
- Applying genomics in regulatory toxicology: a report of the ECETOC workshop on omics threshold on non-adversity.Archives of toxicology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 13 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prior to registering and marketing any new pharmaceutical, (agro)chemical or food ingredient product manufacturers must, by law, generate data to ensure human safety. Safety testing requirements vary depending on sector, but generally repeat-dose testing in animals form the basis for human health risk assessments. Dose level selection is an important consideration when designing such studies, to ensure that exposure levels that lead to relevant hazards are identified. Advice on dose level selection is provided in test guidelines and allied guidance documents, but it is not well harmonised, particularly for selection of the highest dose tested. This paper further builds on concepts developed in a technical report by the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) which recommends pragmatic approaches to dose selection considering regulatory requirements, animal welfare and state of the art scientific approaches. Industry sectors have differing degrees of freedom to operate regarding dose level selection, depending on the purpose of the studies and the regulatory requirements/legislation, and this is reflected in the overall recommended approaches. An understanding of systemic exposure should be utilised where possible (e.g., through toxicokinetic approaches) and used together with apical endpoints from existing toxicity studies to guide more appropriate dose level selection. The highest dose should be limited to a reasonable level, causing minimal but evident toxicity to the test animals without significantly compromising their well-being. As the science of predictive human exposure further develops and matures, this will provide exciting and novel opportunities for more human-relevant approaches to dose level selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.